Atherosclerosis and Vascular Biologic Responses to Estrogens: Histologic, Immunohistochemical, Biochemical, and Molecular Methods

  • Thomas C. Register
  • Susan E. Appt
  • Thomas B. Clarkson
Part of the Methods in Molecular Biology book series (MIMB, volume 1366)

Abstract

Atherogenesis is a multifactorial pathologic process influenced by genetics and environmental factors such as diet, exercise, stress, and other exposures. Estrogen receptors (ER) are expressed in cells of the arterial wall, suggesting that estrogen receptor ligands (estradiol, natural and pharmacologic ligands) may directly affect arterial biology and atherogenesis. Ligand bound estrogen receptor alpha and beta (ERα, ERβ) can influence physiology through direct binding to estrogen response elements in the DNA, through interactions with other transcription factors such as NF-κB, or through rapid effects not dependent on gene expression changes but instead through non-nuclear membrane sites involving ERα, ERβ, or G-coupled protein ER (GPER1).

Elucidation of potential direct effects of estrogens on the artery wall requires careful evaluation of arterial biologic responses to estrogens. We have developed a comprehensive approach to understand the mechanisms of estrogen action which employs histologic measures of the size and other characteristics of atherosclerotic lesions, immunohistochemical assessments of cellular composition, evaluation of chemical, molecular, and genomic changes in the arterial environment, and determination of the relationships between arterial estrogen receptor expression and atherogenesis. This approach can provide important insights into the mechanisms of action of estrogen and other mediators of atherogenesis.

Key words

Atherosclerosis Inflammation Vascular biology Gene expression Macrophage T cell Estrogenreceptoralpha and beta 

Notes

Source of Funding

This project was supported by NIH grants AG18170 (TCR), AG28641 (TCR), and HL45666 (TBC).

References

  1. 1.
    Hansson GK, Robertson AK, Soderberg-Naucler C (2006) Inflammation and atherosclerosis. Annu Rev Pathol 1:297–329CrossRefGoogle Scholar
  2. 2.
    Andersson J, Libby P, Hansson GK (2010) Adaptive immunity and atherosclerosis. Clin Immunol 134(1):33–46CrossRefGoogle Scholar
  3. 3.
    Zhu J, Paul WE (2010) Heterogeneity and plasticity of T helper cells. Cell Res 20(1):4–12CrossRefGoogle Scholar
  4. 4.
    Mendelsohn ME (2002) Protective effects of estrogen on the cardiovascular system. Am J Cardiol 89(12A):12E–17ECrossRefGoogle Scholar
  5. 5.
    Adams MR, Kaplan JR, Manuck SB et al (1990) Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys. Lack of an effect of added progesterone. Arteriosclerosis 10(6):1051–1057CrossRefGoogle Scholar
  6. 6.
    Clarkson TB, Anthony MS, Morgan TM (2001) Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 86(1):41–47PubMedGoogle Scholar
  7. 7.
    Register TC, Cann JA, Kaplan JR et al (2005) Effects of soy isoflavones and conjugated equine estrogens on inflammatory markers in atherosclerotic, ovariectomized monkeys. J Clin Endocrinol Metab 90(3):1734–1740CrossRefGoogle Scholar
  8. 8.
    Register TC, Wagner JD, Zhang L, Hall J, Clarkson TB (2002) Effects of tibolone and conventional hormone replacement therapies on arterial and hepatic cholesterol accumulation and on circulating endothelin-1, vascular cell adhesion molecule-1, and E-selectin in surgically menopausal monkeys. Menopause 9(6):411–421CrossRefGoogle Scholar
  9. 9.
    Speir E, Yu ZX, Takeda K, Ferrans VJ, Cannon RO 3rd (2000) Competition for p300 regulates transcription by estrogen receptors and nuclear factor-kappaB in human coronary smooth muscle cells. Circ Res 87(11):1006–1011CrossRefGoogle Scholar
  10. 10.
    Evans MJ, Eckert A, Lai K, Adelman SJ, Harnish DC (2001) Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res 89(9):823–830CrossRefGoogle Scholar
  11. 11.
    Gavin KM, Seals DR, Silver AE, Moreau KL (2009) Vascular endothelial estrogen receptor alpha is modulated by estrogen status and related to endothelial function and endothelial nitric oxide synthase in healthy women. J Clin Endocrinol Metab 94(9):3513–3520CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Register TC, Adams MR (1998) Coronary artery and cultured aortic smooth muscle cells express mRNA for both the classical estrogen receptor and the newly described estrogen receptor beta. J Steroid Biochem Mol Biol 64(3-4):187–191CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Register TC (2009) Primate models in women’s health: inflammation and atherogenesis in female cynomolgus macaques (Macaca fascicularis). Am J Primatol 71(9):766–775CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Shim GJ, Gherman D, Kim HJ et al (2006) Differential expression of oestrogen receptors in human secondary lymphoid tissues. J Pathol 208(3):408–414CrossRefGoogle Scholar
  15. 15.
    Grodstein F, Stampfer MJ, Manson JE et al (1996) Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 335(7):453–461CrossRefGoogle Scholar
  16. 16.
    Adams MR, Register TC, Golden DL, Wagner JD, Williams JK (1997) Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. Arterioscler Thromb Vasc Biol 17(1):217–221CrossRefGoogle Scholar
  17. 17.
    Zhao J, Imbrie GA, Baur WE et al (2013) Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 33(2):257–265CrossRefGoogle Scholar
  18. 18.
    Hodgin JB, Krege JH, Reddick RL, Korach KS, Smithies O, Maeda N (2001) Estrogen receptor alpha is a major mediator of 17beta-estradiol’s atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 107(3):333–340CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Register TC, Adams MR, Golden DL, Clarkson TB (1998) Conjugated equine estrogens alone, but not in combination with medroxyprogesterone acetate, inhibit aortic connective tissue remodeling after plasma lipid lowering in female monkeys. Arterioscler Thromb Vasc Biol 18(7):1164–1171CrossRefGoogle Scholar
  20. 20.
    Williams JK, Anthony MS, Honore EK et al (1995) Regression of atherosclerosis in female monkeys. Arterioscler Thromb Vasc Biol 15(7):827–836CrossRefGoogle Scholar
  21. 21.
    Anderson GL, Limacher M, Assaf AR et al (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291(14):1701–1712CrossRefGoogle Scholar
  22. 22.
    Rossouw JE, Anderson GL, Prentice RL et al (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefGoogle Scholar
  23. 23.
    Rossouw JE, Prentice RL, Manson JE et al (2007) Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 297(13):1465–1477CrossRefGoogle Scholar
  24. 24.
    Sophonsritsuk A, Appt SE, Clarkson TB, Shively CA, Espeland MA, Register TC (2013) Differential effects of estradiol on carotid artery inflammation when administered early versus late after surgical menopause. Menopause 20(5):540–547PubMedPubMedCentralGoogle Scholar
  25. 25.
    Bullock BC, Lehner ND, Clarkson TB, Feldner MA, Wagner WD, Lofland HB (1975) Comparative primate atherosclerosis. I. Tissue cholesterol concentration and pathologic anatomy. Exp Mol Pathol 22(2):151–175CrossRefGoogle Scholar
  26. 26.
    Clarkson TB, Bond MG, Bullock BC, Marzetta CA (1981) A study of atherosclerosis regression in Macaca mulatta. IV. Changes in coronary arteries from animals with atherosclerosis induced for 19 months and then regressed for 24 or 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol 34(3):345–368CrossRefGoogle Scholar
  27. 27.
    Clarkson TB, Lehner ND, Wagner WD, St Clair RW, Bond MG, Bullock BC (1979) A study of atherosclerosis regression in Macaca mulatta. I. Design of experiment and lesion induction. Exp Mol Pathol 30(3):360–385CrossRefGoogle Scholar
  28. 28.
    Wagner WD, Clarkson TB (1975) Comparative primate atherosclerosis. II. A biochemical study of lipids, calcium, and collagen in atherosclerotic arteries. Exp Mol Pathol 23(1):96–121CrossRefGoogle Scholar
  29. 29.
    Wagner WD, St Clair RW, Clarkson TB (1980) A study of atherosclerosis regression in Macaca mulatta. II. Chemical changes in arteries from animals with atherosclerosis induced for 19 months then regressed for 24 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Exp Mol Pathol 32(2):162–174CrossRefGoogle Scholar
  30. 30.
    Wagner WD, St Clair RW, Clarkson TB, Connor JR (1980) A study of atherosclerosis regression in Macaca mulatta: III. Chemical changes in arteries from animals with atherosclerosis induced for 19 months and regressed for 48 months at plasma cholesterol concentrations of 300 or 200 mg/dl. Am J Pathol 100(3):633–650PubMedPubMedCentralGoogle Scholar
  31. 31.
    Walker SE, Adams MR, Franke AA, Register TC (2008) Effects of dietary soy protein on iliac and carotid artery atherosclerosis and gene expression in male monkeys. Atherosclerosis 196(1):106–113CrossRefGoogle Scholar
  32. 32.
    Walker SE, Register TC, Appt SE et al (2008) Plasma lipid-dependent and -independent effects of dietary soy protein and social status on atherogenesis in premenopausal monkeys: implications for postmenopausal atherosclerosis burden. Menopause 15(5):950–957CrossRefPubMedCentralGoogle Scholar
  33. 33.
    Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM (1994) Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 89(4):1501–1510CrossRefGoogle Scholar
  34. 34.
    Grumbach MM, Auchus RJ (1999) Estrogen: consequences and implications of human mutations in synthesis and action. J Clin Endocrinol Metab 84(12):4677–4694PubMedGoogle Scholar
  35. 35.
    Smith EP, Boyd J, Frank GR et al (1994) Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331(16):1056–1061CrossRefGoogle Scholar
  36. 36.
    Kaplan JR, Adams MR, Anthony MS, Morgan TM, Manuck SB, Clarkson TB (1995) Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Arterioscler Thromb Vasc Biol 15(12):2094–2100CrossRefGoogle Scholar
  37. 37.
    Melendez GC, Register TC, Appt SE, Clarkson TB, Franke AA, Kaplan JR (2015) Beneficial effects of soy supplementation on postmenopausal atherosclerosis are dependent on pretreatment stage of plaque progression. Menopause 22(3):289–296CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Rudel LL, Morris MD (1973) Determination of cholesterol using o-phthalaldehyde. J Lipid Res 14(3):364–366PubMedGoogle Scholar
  39. 39.
    Jackson DS, Cleary EG (1967) The determination of collagen and elastin. Methods Biochem Anal 15:25–76PubMedGoogle Scholar
  40. 40.
    Bergman I, Loxley R (1963) Two improved and simplified methods for the spectrophotometric determination of hydroxyproline. Anal Chem 35(12):1961–1965CrossRefGoogle Scholar
  41. 41.
    Burstein M, Samaille J (1960) On a rapid determination of the cholesterol bound to the serum alpha- and beta-lipoproteins. Clin Chim Acta 5:609CrossRefGoogle Scholar
  42. 42.
    Myers GL, Kimberly MM, Waymack PP, Smith SJ, Cooper GR, Sampson EJ (2000) A reference method laboratory network for cholesterol: a model for standardization and improvement of clinical laboratory measurements. Clin Chem 46(11):1762–1772PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Thomas C. Register
    • 1
  • Susan E. Appt
    • 1
  • Thomas B. Clarkson
    • 1
  1. 1.Department of Pathology, Section on Comparative MedicineWake Forest School of MedicineWinston-SalemUSA

Personalised recommendations